A medication that has been deuterated is a small molecule in which one or more chemical element atoms have been swapped out for isotopes. Isotope replacement is the smallest structural change made to a molecule because the physical properties of the deuterium-heavy chemical element, hydrogen atom, isotope, and hydrogen are almost constant. The market for deuterium-substituted drugs is anticipated to expand dramatically over the next few years as the prevalence of dementia and Alzheimer's disease rises. Additionally, the market for Deuterium-substituted drugs is being benefited by the rise in government-backed measures aimed at setting regulations to stop the global rise in consciousness.
The COVID-19 pandemic had a negative impact on the market due to stringent government actions such as lockdowns to prevent the spread of infection. The prescription rate for deuterium-substituted drugs used to treat Alzheimer's was reduced during the pandemic due to decreased patient visits to clinics and hospitals for treatment and concern for COVID infection, which inhibited market expansion. The COVID-19 pandemic in 2020 impacted most of the region's countries, causing a significant impact on the regional market.
Rising Prevalence of Alzheimer's Disease to Promote Market Growth
The expansion of the deuterium-substituted drugs market is anticipated to be fueled by the increasing prevalence of Alzheimer's disease and the approval of disease-modifying treatments. According to the NCBI, around 6.2 million Americans 65 and older had Alzheimer's disease in 2021; this number is predicted to rise to almost 13.8 million by 2060. Due to their greater life expectancy, women are more likely than men to be diagnosed with Alzheimer's. Additionally, Alzheimer's disease quickly overtakes other neurodegenerative illnesses as the leading cause of death and a major contributor to physical impairment that calls for urgent medical attention. Thus, the growing prevalence of Alzheimer's disease fuels the growth of the deuterium-substituted drugs market.
Side Effects Caused By Deuterium-Substituted Drug To Limit Market Growth
In recent years, deuterium-substituted drug treatment for Alzheimer's has been abandoned. Due to the lack of improvement in cognitive function, very low efficacy in treating Alzheimer's disease symptoms, and the lack of a trustworthy safety profile for the deuterium-substituted drugs medications used in therapy, the incidence of discontinuation is rising. This aspect contributes to the high rates of current medications being stopped due to adverse effects, preventing the market for deuterium-substituted drugs from expanding during the anticipated period. Additionally, the market growth rate will also be slowed down by high expenses related to research and development, rising costs of medications that have not yet received official approval from the relevant authorities, and subpar healthcare facilities in developing nations.
Based on type, the deuterium-substituted drugs market is segmented into drugs in clinical trials and marketed drugs. The drugs in the clinical trials category dominated the market in 2022. Roughly a dozen businesses are actively pursuing the deuterium-substituted drugs industry. Most medication formulators and developers are smaller companies that rely on alliances for co-development, marketing, and distribution. The development of roughly 20 potentially significant deuterium-substituted drugs is underway. Numerous drugs are working to treat conditions, including regulating neurotransmitters, transmembrane conductance, protease activity, inflammation, control of mitochondrial function, and antineoplastic.
Based on application, the deuterium-substituted drugs market is segmented into hospitals, clinics and others. The hospital category dominated the market in 2022 due to an increase in the aging population and Alzheimer's patients, causing a spike in hospitalization. In the senior population, there are 518 hospitalizations per 1,000 Medicare beneficiaries who have Alzheimer's or another form of dementia, compared to only 234 hospitalizations per 1,000 Medicare beneficiaries who do not have these conditions, according to the Alzheimer's Association report 2022. However, considering the prevalence of Alzheimer's disease, it is anticipated that the overall number of hospitalizations for AD patients will stay low.
North America is projected to hold the largest share of the deuterium-substituted drugs market over the forecast period because more research and development is being done in this area and because significant important companies are focusing more on improving deuterium-substituted drugs. The deuterium-substituted drugs market is also expanding due to the expanding research into Alzheimer's treatment. On the other hand, the Asia Pacific deuterium-substituted drugs market is anticipated to grow significantly due to the region's growing Alzheimer's disease prevalence and rising healthcare costs. The growing older population in this region will further accelerate the deuterium-substituted drugs market's growth rate.
LIST OF KEY COMPANIES PROFILED:
- Bristol-Myers Squibb
- Jazz Pharmaceuticals
- Hinova Pharmaceuticals Inc.
|Market Size in 2022||USD 241.2 Million|
|Market Forecast in 2030||USD 326.9 Million|
|Compound Annual Growth Rate||5.20%|
|Unit||Revenue (USD Million) and Volume (Kilo Tons)|
|Segmentation||By Type, By Application and By Geography|